WASHINGTON — Health secretary Robert F. Kennedy Jr. was uncharacteristically chummy with pharma executives at the White House on Thursday as he cheered the Trump administration’s plan for lowering obesity medication […]
Read MoreFDA’s ‘key man’ Peter Marks is out. Biotech investors will now deal with the consequences
Robert F. Kennedy Jr. forcing Peter Marks out of the Food and Drug Administration has blown a hole in the agency’s leadership ranks and threatens to unmoor the oversight of […]
Read MoreJ&J to buy Intra-Cellular Therapies in deal worth $14.6B
Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will […]
Read More